Navigation Links
Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results
Date:5/15/2009

58,072,984 54,558,259 COMMITMENTS AND CONTINGENCIES SHAREHOLDERS' EQUITY: Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding -- -- Common stock, $0.001 par value, 100,000,000 shares authorized, 19,169,805 and 19,094,805 shares issued and outstanding as of December 31, 2008 and June 30, 2008, respectively 19,170 19,095 Paid-in capital 20,464,837 19,987,708 Statutory reserves 3,004,008 2,894,902 Retained earnings 18,521,982 19,136,577 Accumulated other comprehensive income 4,944,279 4,717,121 Total shareholders' equity 46,954,276 46,755,403 Total liabilities and shareholders' equity $ 105,027,260 $ 101,313,662 Shengtai Pharmaceutical, Inc. Consolidated Statements of Income and Other Comprehensive Income For the three and nine months ended March 31, 2009 and 2008 (Unaudited) Three months ended Nine months ended March 31, March 31, 2009 2008 2009 2008 SALES REVENUE $ 16,301,522 $ 20,701,577 $ 49,220,996 $ 65,028,934 COST OF SALES 15,283,929 16,220,665 43,016,707 50,085,971 GROSS PROFIT 1,017,593 4,480,912 6,204,289 14,942,963 SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 1,322,178 1,603,932 6,074,853 5,114,863 INCOME (LOSS) FROM OPERATIONS (3
'/>"/>
SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Shengtai Pharmaceutical Schedules 2009 Third Quarter Financial Results and Conference Call
2. Shengtai Pharmaceutical Hosts Key Customers at Its Headquarters for Facility Tour and Technology Exchange Conference
3. Shengtai Pharmaceutical, Inc. Comments On Its Operations
4. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
5. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
6. Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference
7. Shengtai Pharmaceutical Expands International Sales Program
8. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
9. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
10. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
11. Shengtai Pharmaceutical, Inc. to Present at Roth Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...easingly common but more easily identified, study ...s) -- A magnetic resonance imaging test is highly...cy complication called placenta accreta, researche...enta surrounding a fetus attaches too deeply to a ...pull out parts of the uterine wall, rupturing bloo...
(Date:12/1/2009)... CAEAR Foundation Changes Name to HealthHIV , ...e CAEAR Foundation, one of the largest national HI...o HealthHIV and launching a new website. The annou... of a campaign to promote the organization’s... , , , ,“HealthHIV clearly, quickly and eas...
(Date:12/1/2009)...NS, Dec. 1 The American...professional association of blood specialists, exp...nual Meeting from December 5-8, 2009, at the Ernes...The meeting will showcase the latest research and ...leasure to host ASH,s 51st annual meeting, where w...
(Date:12/1/2009)...TON, Dec. 1 On December...,538 federal prisoners were HIV positive or had co...S) in the Office of Justice Programs, U.S. Departm...an estimated 5,672 inmates in state and federal pr... In 2007, about 43 per 10,000 prison inmates were ...
(Date:12/1/2009)...evelopment of simple screening test, expert says ,...n a finding that could lead to a simple blood test...identified immune system markers that indicate ear...ng cancer. , The researchers examined gene expr...with non-small cell lung cancer and a control grou...
Breaking Medicine News(10 mins):Health News:Serious Pregnancy Complication Detected With MRI 2Health News:National HIV Non-Profit Announces New Name 2Health News:51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care 2Health News:51st Annual Meeting of the American Society of Hematology Will Highlight Research and Policy Changes Affecting Medical Practice and Patient Care 3Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 2Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 3Health News:Gene 'Signature' May Point to Lung Cancer 2
...benefits, but surgeons rethinking,one-size-fits-al...ients,who undergo foot and ankle surgery are recov...ks to new minimal incision techniques and tools. A...sions for the,sake of small incisions," says Lawre...
... LifeMasters Supported SelfCare,Inc., a national ... that it,has received an extension from the Center...sease management demonstration project in Florida....e,fee for service beneficiaries (Medicare/Medicaid...
...over the American Stroke Associations Internationa...08 at the Ernest N. Morial Convention Center in Ne...in the world of medical scientists and physicians ...ond year, the American Association of Neurological...
...Feb. 19 The Ensign,Group, Inc. (Nasdaq: ENSG ), ...led nursing, rehabilitative care services and assi...Park skilled nursing facility in,Tucson, Arizona h...p://www.newscom.com/cgi-bin/prnh/20071213/LATH168L...
...ary 19, 2008 New findings show that a specialized...ling genes can selectively target tumors in the br...sue remained virtually untouched, according to a F..., Most importantly, this study finds that the vir...
...rly Kent, the daughter of,Virginia Kent, Deceased,...urt for her mother,s death, which was caused by th...g Company immunity law is being challenged., All ...smissed and all Michigan victims were denied compe...
Other Medicine News:Health News:Surgeons Rethink Approach to Minimal Incision Foot and Ankle Surgery 2Health News:The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida 2Health News:The Centers for Medicare & Medicaid Services Extends LifeMasters Demonstration Project in Florida 3Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 2Health News:The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program 3Health News:Tumor-killing virus selectively targets diseased brain cells 2Health News:Michigan Resident, Kimberly Kent's Drug Product Liability Case Will Be Argued in the United States Supreme Court on February 25, 2008 2
(Date:12/1/2009)...RRY HILL, N.J., Dec. 1 F...rprised and delighted when his radiotherapy treatm...0 minutes each day to less than five. Midway thro...are Valley Urology Cancer Center acquired the re...gy from Varian Medical Systems (NYSE: VAR ), ma...
(Date:12/1/2009)... Calif., Dec. 1 The new position o...Microchip Biotechnologies, Inc. has been taken up ...ve with more than 30 years of experience creating ...r. Goldstein will direct Microchip Biotechnologies...mer service operations as the company makes the tr...
(Date:12/1/2009)... and TOKYO, Dec. 1 Galenea Corp. a... the further extension of their research and devel...tension increases the collaboration term to seven ...proximately $90 million. The companies have been ...of discovering and developing first-in-class thera...
Breaking Medicine Technology:Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 2Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 3Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 4Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center 5Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3First Pediatric Patient Treated With Aptocine 28TM 29 a Novel Light Activated Drug in Neurofibromatosis Study 13528 1First Pediatric Patient Treated With Aptocine 28TM 29 a Novel Light Activated Drug in Neurofibromatosis Study 13528 2First Pediatric Patient Treated With Aptocine 28TM 29 a Novel Light Activated Drug in Neurofibromatosis Study 13528 3Sage Software Healthcare Inc Celebrates National Health Center Week 54311 1Sage Software Healthcare Inc Celebrates National Health Center Week 54311 2Goold Health Systems Accelerates Backups by 5 times Using Arkeia Network Backup 54309 1Goold Health Systems Accelerates Backups by 5 times Using Arkeia Network Backup 54309 2Goold Health Systems Accelerates Backups by 5 times Using Arkeia Network Backup 54309 3
...allisto Pharmaceuticals,Inc. (Amex: KAL; FWB: CA4)...against cancer and inflammatory diseases, announce...clinical trial of Atiprimod to treat low to,interm...rcinoid cancer).,With the addition of the Robert H...n University, 676 N. St. Clair Street, Suite 850, ...
... Give Molecular Laboratories Increased Efficiencie... Test, Which Surpasses, Standard-of-Care Sensitiv... Measure All Known Strains of HIV-1,...has received a supplemental Premarket Approval fro...cently introduced RealTime HIV-1 viral load test.,...
Other Medicine Technology:Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients 2Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients 3Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients 4Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 2Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 3Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 4Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 5Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test 6
...rosol Resistant Tips offer a safe alternative to u... designed for applications such as PCR(a), pipetti...ddition, ART Tips are excellent for tissue culture...dies. ART Tips prevent aerosol contaminants and li...
Tipack (Sterilized) D1000
MBP 1000GGenomic Tip
...Premium Low Binding, Graduated, Long Reach Pipet T...d protein binding. Non-reactive. Beveled and refer...s up to 10 L. Produced & packaged completely by au...e Racked packaged 96 tips/rack and 10 racks/cs. AV...
Medicine Products: